^
Association details:
| Biomarker: | CBL mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia
Published date:
11/01/2018
Excerpt:
We retrospectively analyzed a combined cohort of 111 pts treated with CPX-351 from Moffitt Cancer Center...In contrast, RR were significantly lower in pts with TP53 (33.3%; n=18, p=0.03) or CBL (14.3%; n=7, p=0.04 mutations.
DOI:
10.1182/blood-2018-99-117412
